Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan. Issue 9 (14th July 2021)

• Record Type: Journal Article
• Authors: Izutsu, Koji; Ando, Kiyoshi; Nishikori, Momoko; Shibayama, Hirohiko; Teshima, Takanori; Kuroda, Junya; Kato, Koji; Imaizumi, Yoshitaka; Nosaka, Kisato; Sakai, Rika; Hojo, Seiichiro; Nakanishi, Tadashi; Rai, Shinya
• Is Part Of: Cancer science. Volume 112:Issue 9(2021)
• Page Start: 3627
• Page End: 3635
• Publication Date: 2021-07-14
• Subjects: efficacy -- enhancer of zeste homolog 2 -- follicular lymphoma -- non‐Hodgkin lymphoma -- safety -- tazemetostat -- trimethylation of lysine 27 in histone 3; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.15040
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Tazemetostat is a selective, reversible, small‐molecule inhibitor of the histone methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open‐label, phase II study, we assessed the efficacy and safety of tazemetostat in Japanese patients with relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma harboring the EZH2 mutation. Tazemetostat (800 mg twice daily) was given orally (28‐day cycle) until disease progression or unacceptable toxicity. Among the 20 eligible patients, 17 were enrolled in cohort 1 (follicular lymphoma [FL]), and three were enrolled in cohort 2 (diffuse large B‐cell lymphoma). At data cut‐off, the objective response rate in cohort 1 was 76.5%, including six patients (35.3%) with complete response and seven patients (41.2%) with partial response (PR). All three patients in cohort 2 achieved PR. In cohort 1, median progression‐free survival (PFS) was not reached at the median follow‐up of 12.9 months. The estimated PFS rate at 12 and 15 months was 94.1% and 73.2%, respectively. The most common grade 3 treatment‐emergent adverse event (TEAE) was lymphopenia (n = 2). Grade 4 TEAEs included hypertriglyceridemia and pneumonia aspiration (n = 1 each), which were not related to tazemetostat. Treatment‐emergent adverse events leading to study drug discontinuation were reported in four of the 20 patients, indicating that the safety profile of tazemetostat was acceptable and manageable. Tazemetostat 800 mg twice daily showed encouraging efficacy in patients with R/R EZH2 mutation‐positive FL with a manageable safety profile in the overall population. Thus, tazemetostat could be a potential treatment for R/R EZH2 mutation‐positive FL. Abstract : Percentage change from baseline in sum of the product of the perpendicular diameters of target lesions based on independent reviewer assessment.